靶向JAK-STAT信号通路治疗银屑病的研究进展

doi:10.35541/cjd.20200715

Abstract

Abstract: 【Abstract】 The Janus kinase （JAK）-signal transducer and activator of transcription （STAT） signaling pathway is closely related to the occurrence of psoriasis. Various cytokines, including interleukin （IL）-23, IL-22, interferon （IFN）-γ , etc., can promote some key pathologic processes （such as the proliferation and abnormal differentiation of keratinocytes, and infiltration of inflammatory cells） via the JAK-STAT pathway in psoriasis, which suggests that targeting JAK-STAT pathway is a new strategy for the treatment of psoriasis. In recent years, small-molecule JAK inhibitors have shown good efficacy and safety in the treatment of psoriasis, and drugs targeting STAT pathway have been under development, which provide more treatment options for psoriasis. This review summarizes progress in drugs targeting JAK-STAT signaling pathway in the treatment of psoriasis.

Key words: Psoriasis, Janus kinases, STAT transcription factors, Therapy, JAK-STAT pathway, JAK inhibitors, STAT inhibitors

He Xie, Li Yuzhen. Targeting the JAK-STAT signaling pathway in the treatment of psoriasis[J]. Chinese Journal of Dermatology, 2023, 56(3): 273-278.doi:10.35541/cjd.20200715

References ［54］

［1］	Banerjee S, Biehl A, Gadina M, et al. JAK⁃STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects［J］. Drugs, 2017,77（5）:521⁃546. doi: 10.1007/s40265⁃017⁃0701⁃9.
［2］	Ciechanowicz P, Rakowska A, Sikora M, et al. JAK⁃inhibitors in dermatology: current evidence and future applications［J］. J Dermatolog Treat, 2019,30（7）:648⁃658. doi: 10.1080/09546634. 2018.1546043.
［3］	Chen M, Dai SM. A novel treatment for psoriatic arthritis: Janus kinase inhibitors［J］. Chin Med J （Engl）, 2020,133（8）:959⁃967.doi: 10.1097/CM9.0000000000000711.
［4］	Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases［J］. Nat Rev Drug Discov, 2017,16（12）:843⁃862. doi: 10.1038/nrd.2017.201.
［5］	Chalmin F, Humblin E, Ghiringhelli F, et al. Transcriptional programs underlying Cd4 T cell differentiation and functions［J］. Int Rev Cell Mol Biol, 2018,341:1⁃61. doi: 10.1016/bs.ircmb. 2018.07.002.
［6］	Long D, Chen Y, Wu H, et al. Clinical significance and immunobiology of IL⁃21 in autoimmunity［J］. J Autoimmun, 2019,99:1⁃14. doi: 10.1016/j.jaut.2019.01.013.
［7］	Yang L, Li B, Dang E, et al. Impaired function of regulatory T cells in patients with psoriasis is mediated by phosphorylation of STAT3［J］. J Dermatol Sci, 2016,81（2）:85⁃92. doi: 10.1016/j.jdermsci.2015.11.007.
［8］	Chen L, Shen Z. Tissue⁃resident memory T cells and their biological characteristics in the recurrence of inflammatory skin disorders［J］. Cell Mol Immunol, 2020,17（1）:64⁃75. doi: 10. 1038/s41423⁃019⁃0291⁃4.
［9］	Deng Y, Wang Z, Chang C, et al. Th9 cells and IL⁃9 in autoimmune disorders: pathogenesis and therapeutic potentials［J］. Hum Immunol, 2017,78（2）:120⁃128. doi: 10.1016/j.humimm. 2016.12.010.
［10］	Morelli M, Scarponi C, Mercurio L, et al. Selective immunomodulation of inflammatory pathways in keratinocytes by the Janus kinase （JAK） inhibitor tofacitinib: implications for the employment of JAK⁃targeting drugs in psoriasis［J］. J Immunol Res, 2018,2018:7897263. doi: 10.1155/2018/7897263.
［11］	Johansen C, Rittig AH, Mose M, et al. STAT2 is involved in the pathogenesis of psoriasis by promoting CXCL11 and CCL5 production by keratinocytes［J/OL］. PLoS One, 2017,12（5）:e0176994. doi: 10.1371/journal.pone.0176994.
［12］	Liu L, Wu Y, Cao K, et al. Shikonin inhibits IFN⁃γ⁃induced K17 over⁃expression of HaCaT cells by interfering with STAT3 signaling［J］. Int J Clin Exp Pathol, 2015,8（8）:9202⁃9207.
［13］	Papp KA, Menter MA, Raman M, et al. A randomized phase 2b trial of baricitinib, an oral Janus kinase （JAK） 1/JAK2 inhibitor, in patients with moderate⁃to⁃severe psoriasis［J］. Br J Dermatol, 2016,174（6）:1266⁃1276. doi: 10.1111/bjd.14403.
［14］	Punwani N, Scherle P, Flores R, et al. Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis［J］. J Am Acad Dermatol, 2012,67（4）:658⁃664. doi: 10.1016/j.jaad.2011.12.018.
［15］	Krueger J, Clark JD, Suárez⁃Fariñas M, et al. Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: a randomized phase 2 study［J］. J Allergy Clin Immunol, 2016,137（4）:1079⁃1090. doi: 10.1016/j.jaci.2015.12.1318.
［16］	Abdulrahim H, Sharlala H, Adebajo AO. An evaluation of tofacitinib for the treatment of psoriatic arthritis［J］. Expert Opin Pharmacother, 2019,20（16）:1953⁃1960. doi: 10.1080/14656566. 2019.1657404.
［17］	Burmester GR, Curtis JR, Yun H, et al. An integrated analysis of the safety of tofacitinib in psoriatic arthritis across phase III and long⁃term extension studies with comparison to real⁃world observational data［J］. Drug Saf, 2020,43（4）:379⁃392. doi: 10.1007/s40264⁃020⁃00904⁃9.
［18］	Strober BE, Gottlieb AB, van de Kerkhof P, et al. Benefit⁃risk profile of tofacitinib in patients with moderate⁃to⁃severe chronic plaque psoriasis: pooled analysis across six clinical trials［J］. Br J Dermatol, 2019,180（1）:67⁃75. doi: 10.1111/bjd.17149.
［19］	Zhang J, Tsai TF, Lee MG, et al. The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: aphase 3, randomized, double⁃blind, placebo⁃controlled study［J］. J Dermatol Sci, 2017,88（1）:36⁃45. doi: 10. 1016/j.jdermsci.2017.05.004.
［20］	Papp KA, Bissonnette R, Gooderham M, et al. Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a phase 2b randomized clinical trial［J］. BMC Dermatol, 2016,16（1）:15. doi: 10.1186/s12895⁃016⁃0051⁃4.
［21］	Kathuria H, Nguyen D, Handral HK, et al. Proposome for transdermal delivery of tofacitinib［J］. Int J Pharm, 2020,585:119558. doi: 10.1016/j.ijpharm.2020.119558.
［22］	Mössner R, Hoff P, Mohr J, et al. Successful therapy of palmoplantar pustulosis with tofacitinib⁃report on three cases［J］. Dermatol Ther, 2020,33（4）:e13753. doi: 10.1111/dth.13753.
［23］	Wang YA, Rosenbach M. Successful treatment of refractory tumor necrosis factor inhibitor⁃induced palmoplantar pustulosis with tofacitinib: report of case［J］. JAAD Case Rep, 2020,6（2）:115⁃118. doi: 10.1016/j.jdcr.2019.12.006.
［24］	Shibata T, Muto J, Hirano Y, et al. Palmoplantar pustulosis⁃like eruption following tofacitinib therapy for juvenile idiopathic arthritis［J］. JAAD Case Rep, 2019,5（6）:518⁃521. doi: 10.1016/j.jdcr.2019.03.024.
［25］	Koumaki D, Koumaki V, Lagoudaki E, et al. Palmoplantar pustulosis⁃like eruption induced by baricitinib for treatment of rheumatoid arthritis［J］. Eur J Case Rep Intern Med, 2020,7（1）:001383. doi: 10.12890/2019_001383.
［26］	Di Domizio J, Castagna J, Algros MP, et al. Baricitinib⁃induced paradoxical psoriasis［J］. J Eur Acad Dermatol Venereol, 2020,34（8）:e391⁃e393. doi: 10.1111/jdv.16293.
［27］	Forman SB, Pariser DM, Poulin Y, et al. TYK2/JAK1 inhibitor PF⁃06700841 in patients with plaque psoriasis: phase IIa, randomized, double⁃blind, placebo⁃controlled trial［J］. J Invest Dermatol, 2020,140（12）:2359⁃2370. doi: 10.1016/j.jid.2020.03. 962.
［28］	Works MG, Yin F, Yin CC, et al. Inhibition of TYK2 and JAK1 ameliorates imiquimod⁃induced psoriasis⁃like dermatitis by inhibiting IL⁃22 and the IL⁃23/IL⁃17 axis［J］. J Immunol, 2014,193（7）:3278⁃3287. doi: 10.4049/jimmunol.1400205.
［29］	Papp K, Pariser D, Catlin M, et al. A phase 2a randomized, double⁃blind, placebo⁃controlled, sequential dose⁃escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate⁃to⁃severe psoriasis［J］. Br J Dermatol, 2015,173（3）:767⁃776. doi: 10.1111/bjd.13745.
［30］	Jones P, Storer RI, Sabnis YA, et al. Design and synthesis of a pan⁃Janus kinase inhibitor clinical candidate （PF⁃06263276） suitable for inhaled and topical delivery for the treatment of inflammatory diseases of the lungs and skin［J］. J Med Chem, 2017,60（2）:767⁃786. doi: 10.1021/acs.jmedchem.6b01634.
［31］	Tanimoto A, Shinozaki Y, Yamamoto Y, et al. A novel JAK inhibitor JTE⁃052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: comparison with conventional therapeutic agents［J］. Exp Dermatol, 2018,27（1）:22⁃29. doi: 10.1111/exd.13370.
［32］	Mease P, Coates LC, Helliwell PS, et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis （EQUATOR）: results from a randomised, placebo⁃controlled, phase 2 trial［J］. Lancet, 2018,392（10162）:2367⁃2377. doi: 10.1016/S0140⁃6736（18）32483⁃8.
［33］	Orbai AM, Ogdie A, Gossec L, et al. Effect of filgotinib on health⁃related quality of life in active psoriatic arthritis: a randomized phase 2 trial （EQUATOR）［J］. Rheumatology （Oxford）, 2020,59（7）:1495⁃1504. doi: 10.1093/rheumatology/kez408.
［34］	Bissonnette R, Luchi M, Fidelus⁃Gort R, et al. A randomized, double⁃blind, placebo⁃controlled, dose⁃escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis［J］. J Dermatolog Treat, 2016,27（4）:332⁃338. doi: 10.3109/09546634. 2015.1115819.
［35］	Schmieder GJ, Draelos ZD, Pariser DM, et al. Efficacy and safety of the Janus kinase 1 inhibitor PF⁃04965842 in patients with moderate⁃to⁃severe psoriasis: phase II, randomized, double⁃blind, placebo⁃controlled study［J］. Br J Dermatol, 2018,179（1）:54⁃62. doi: 10.1111/bjd.16004.
［36］	Ludbrook VJ, Hicks KJ, Hanrott KE, et al. Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo⁃controlled phase IIa study［J］. Br J Dermatol, 2016,174（5）:985⁃995. doi: 10.1111/bjd.14399.
［37］	Burke JR, Cheng L, Gillooly KM, et al. Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain［J］. Sci Transl Med, 2019,11（502）:eaaw1736. doi: 10.1126/scitranslmed.aaw1736.
［38］	Papp K, Gordon K, Thaçi D, et al. Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis［J］. N Engl J Med, 2018,379（14）:1313⁃1321. doi: 10.1056/NEJMoa1806382.
［39］	Singh R, Pradhan V, Roberts ES, et al. Safety and pharmacokinetics of the oral TYK2 inhibitor PF⁃06826647: a phase I, randomized, double⁃blind, placebo⁃controlled, dose⁃escalation study［J/OL］. Clin Transl Sci, 2020［2021⁃02⁃02］.https://ascpt.onlinelibrary.wiley.com/doi/10.1111/cts.12929. doi: 10.1111/cts.12929.
［40］	Miyoshi K, Takaishi M, Nakajima K, et al. Stat3 as a therapeutic target for the treatment of psoriasis: a clinical feasibility study with STA⁃21, a Stat3 inhibitor［J］. J Invest Dermatol, 2011,131（1）:108⁃117. doi: 10.1038/jid.2010.255.
［41］	Park JS, Kwok SK, Lim MA, et al. STA⁃21, a promising STAT⁃3 inhibitor that reciprocally regulates Th17 and Treg cells, inhibits osteoclastogenesis in mice and humans and alleviates autoimmune inflammation in an experimental model of rheumatoid arthritis［J］. Arthritis Rheumatol, 2014,66（4）:918⁃929. doi: 10.1002/art.38305.
［42］	Kim JY, Ahn J, Kim J, et al. Nanoparticle⁃assisted transcutaneous delivery of a signal transducer and activator of transcription 3⁃inhibiting peptide ameliorates psoriasis⁃like skin inflammation［J］. ACS Nano, 2018,12（7）:6904⁃6916. doi: 10. 1021/acsnano.8b02330.
［43］	Schöneberger H, Weiss A, Brill B, et al. The integration of a Stat3 specific peptide aptamer into the thioredoxin scaffold protein strongly enhances its inhibitory potency［J］. Horm Mol Biol Clin Investig, 2011,5（1）:1⁃9. doi: 10.1515/HMBCI.2011. 013.
［44］	Mack L, Brill B, Delis N, et al. Stat3 is activated in skin lesions by the local application of imiquimod, a ligand of TLR7, and inhibited by the recombinant peptide aptamer rS3⁃PA［J］. Horm Mol Biol Clin Investig, 2012,10（2）:265⁃272.doi: 10.1515/hmbci⁃2012⁃0007.
［45］	Miyoshi K, Takaishi M, Digiovanni J, et al. Attenuation of psoriasis⁃like skin lesion in a mouse model by topical treatment with indirubin and its derivative E804［J］. J Dermatol Sci, 2012,65（1）:70⁃72. doi: 10.1016/j.jdermsci.2011.10.001.
［46］	Tang L, He S, Wang X, et al. Cryptotanshinone reduces psoriatic epidermal hyperplasia via inhibiting the activation of STAT3［J］. Exp Dermatol, 2018,27（3）:268⁃275. doi: 10.1111/exd.13511.
［47］	Skyvalidas DΝ, Mavropoulos A, Tsiogkas S, et al. Curcumin mediates attenuation of pro⁃inflammatory interferon γ and interleukin 17 cytokine responses in psoriatic disease, strengthening its role as a dietary immunosuppressant［J］. Nutr Res, 2020,75:95⁃108. doi: 10.1016/j.nutres.2020.01.005.
［48］	Marepally S, Boakye CH, Patel AR, et al. Topical administration of dual siRNAs using fusogenic lipid nanoparticles for treating psoriatic⁃like plaques［J］. Nanomedicine （Lond）, 2014,9（14）:2157⁃2174. doi: 10.2217/nnm.13.202.
［49］	Ran LW, Wang H, Lan D, et al. Effect of RNA interference targeting STAT3 gene combined with ultrasonic irradiation and SonoVue microbubbles on proliferation and apoptosis in keratinocytes of psoriatic lesions［J］. Chin Med J （Engl）, 2018,131（17）:2097⁃2104. doi: 10.4103/0366⁃6999.239297.
［50］	Ran LW, Wang H, Lan D, et al. Effects of RNA interference combined with ultrasonic irradiation and SonoVue microbubbles on expression of STAT3 gene in keratinocytes of psoriatic lesions［J］. J Huazhong Univ Sci Technolog Med Sci, 2017,37（2）:279⁃285. doi: 10.1007/s11596⁃017⁃1728⁃6.
［51］	Hu XP, Xie Q, Chen CF, et al. Let⁃7a inhibits T⁃cell proliferation and IFN⁃γ secretion by down⁃regulating STAT3 expression in patients with psoriasis［J］. Cell Physiol Biochem, 2017,42（1）:115⁃125. doi: 10.1159/000477120.
［52］	Chowdhari S, Saini N. hsa⁃miR⁃4516 mediated downregulation of STAT3/CDK6/UBE2N plays a role in PUVA induced apoptosis in keratinocytes［J］. J Cell Physiol, 2014,229（11）:1630⁃1638. doi: 10.1002/jcp.24608.
［53］	Wang Y, Yu X, Wang L, et al. miR⁃320b is down⁃regulated in psoriasis and modulates keratinocyte proliferation by targeting AKT3［J］. Inflammation, 2018,41（6）:2160⁃2170. doi: 10.1007/s10753⁃018⁃0859⁃7.
［54］	Yan JJ, Qiao M, Li RH, et al. Downregulation of miR⁃145⁃5p contributes to hyperproliferation of keratinocytes and skin inflammation in psoriasis［J］. Br J Dermatol, 2019,180（2）:365⁃372. doi: 10.1111/bjd.17256.

[1]	Ren Fenfen, Wang Peng, Zhang Jingzhan, Kang Xiaojing. Network pharmacology-based prediction of potential effective components of traditional Chinese medicine and their molecular mechanisms of action in the anti-angiogenic treatment of Kaposi′s sarcoma [J]. Chinese Journal of Dermatology, 2023, 0(3): 20220140-e20220140.
[2]	Yuan Chen, Yan Yan, Wang Baoxi . Biotherapy for acne inversa [J]. Chinese Journal of Dermatology, 2023, 56(3): 270-273.
[3]	Ruan Shifan, Zhang Peng, Lin Tingting, Luo Renwei, Bao Siyi, Xue Chenyao, Tong Zequn, Zhang Liangliang, Gong Ting, Ji Chao, . Correlations between psoriasis vulgaris and dyslipidemia [J]. Chinese Journal of Dermatology, 2023, 0(3): 20220322-e20220322.
[4]	Jin Shiying, Shi Jinjun, Gao Qi, Chen Mei, Dong Zhengbang, Yan Qiao, Li Jijian, Wang Fei. High-frequency ultrasonography-assisted evaluation of treatment outcomes of erysipelas: a prospective controlled study [J]. Chinese Journal of Dermatology, 2023, 0(3): 20220337-e20220337.
[5]	Committee on Psoriasis, Chinese Society of Dermatology. Expert consensus on treat-to-target approach for the treatment of psoriasis with biological agents [J]. Chinese Journal of Dermatology, 2023, 56(3): 191-203.
[6]	Zhou Jian, Yu Chen, Wang Gang. Clinical efficacy and safety of secukinumab in the treatment of 13 cases of refractory localized pustular psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(3): 247-251.
[7]	Hu Kun, Yang Jing, Wang Qiaolin, Chen Junchen, Zhang Mi, Zhu Wu, Zhang Bin, Dou Guanshen, Wendong Chen, Kuang Yehong. Real-world short-term treatment effects of Ixekizumab in Chinese patients with psoriasis: a single-center retrospective study [J]. Chinese Journal of Dermatology, 2023, 56(3): 210-215.
[8]	Luo Shuaihantian, Long Hai, Lu Qianjin, . Research advances in systemic lupus erythematosus in 2022 [J]. Chinese Journal of Dermatology, 2023, 56(3): 266-269.
[9]	Chen Lianghong, Sun Yan, Wang Jingyu, Wu Yan. Benvitimod for the treatment of dermatoses [J]. Chinese Journal of Dermatology, 2023, 0(2): 20210875-e20210875.
[10]	Tian Jing, Liang Yuan, Ma Lin. Dupilumab in the treatment of childhood atopic dermatitis [J]. Chinese Journal of Dermatology, 2023, 0(2): 20210730-e20210730.
[11]	Yang Aimin, Chen Jiangwei, Huang Jiacheng, Cen Ying, Chen Junjie. Treatment of Merkel cell carcinoma [J]. Chinese Journal of Dermatology, 2023, 0(2): 20210536-e20210536.
[12]	Wang Zhaoyang, Xiang Xin, Chen Yunliu, Miao Chaoyang, Zhao Xinrong, Zhang Zhenhua, Liu Yuanxiang, Ma Lin, Xu Zigang. Comparison of efficacy and safety of biologics versus methotrexate in the treatment of severe pediatric plaque psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(2): 112-117.
[13]	Jia Yuanyuan, Mao Qiuyu, Yang Jingyi, Min Wei. Efficacy of dupilumab in the treatment of moderate and severe atopic dermatitis in the elderly: a clinical observation [J]. Chinese Journal of Dermatology, 2023, 56(2): 125-129.
[14]	Chinese Society of Dermatology, Chinese Association of Rehabilitation Dermatology, Combination of Traditional and Western Medicine Dermatology, The Dermatology Branch of Chinese Medical Education Association. Expert consensus on diagnosis and treatment of senile herpes zoster [J]. Chinese Journal of Dermatology, 2023, 56(2): 97-104.
[15]	Chen Qitao, Li Yuqian, Shao Guanghui, Zhu Jing, Zhu Qilin, Li Zhongming, Du Xufeng, Fan Weixin. Erosive pustular dermatosis of the scalp [J]. Chinese Journal of Dermatology, 2023, 0(2): 20210803-e20210803.

Targeting the JAK-STAT signaling pathway in the treatment of psoriasis

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［54］

Related Articles 15

Metrics

Comments

Recommended 10